SCHEMBL4892230

SCHEMBL4892230

Cc1cc(C(C)NC(=O)Nc2ccc(Br)cc2C(=O)N2C[C@H](C)C[C@H](C)C2)n[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
MAPK1 P28482 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 2/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
FPR2 P25090 1/20 0.33
ALDH1A1 P00352 3/20 0.32
HTT P42858 2/20 0.32
TSHR P16473 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
POLB P06746 1/20 0.32
CACNA1B Q00975 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892981 0.80 KDM4E (0.39) KDM4EMAPK1L3MBTL1SMN1; SMN2GAA
SCHEMBL4895438 0.78 KDM4E (0.41) KDM4EMAPK1L3MBTL1SMN1; SMN2GAA
SCHEMBL4895424 0.78 KDM4E (0.41) KDM4EMAPK1L3MBTL1SMN1; SMN2GAA
SCHEMBL4884281 0.76 KDM4E (0.44) KDM4EMAPK1L3MBTL1SMN1; SMN2GAA
SCHEMBL4896496 0.75 ALDH1A1 (0.44) KDM4EMAPK1L3MBTL1SMN1; SMN2GAA
SCHEMBL4884311 0.72 KDM4E (0.48) KDM4EL3MBTL1SMN1; SMN2GAAMEN1
SCHEMBL4893007 0.72 KDM4E (0.41) KDM4EL3MBTL1SMN1; SMN2GAAMEN1
SCHEMBL4892012 0.72 KDM4E (0.41) KDM4EL3MBTL1SMN1; SMN2GAAMEN1
SCHEMBL4893019 0.72 KDM4E (0.41) KDM4EL3MBTL1SMN1; SMN2GAAMEN1
SCHEMBL4884321 0.71 KDM4E (0.47) KDM4EMAPK1L3MBTL1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200512-A1 Hepatitis C virus polymerase inhibitors BLANEY JEFFREY MARK 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200512-A1 Hepatitis C virus polymerase inhibitors SSU72, POLR2H, POLR2E KDM4E 2519/4885MAPK1 3579/4885L3MBTL1 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.